Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.11.2023 | Case report

Capecitabine/temozolomide

Nausea, diarrhoea and thrombocytopenia : 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Brighi N, et al. Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors. Current Oncology 30: 1381-1394, No. 2, 18 Jan 2023. Available from: URL: https://www.mdpi.com/journal/curroncol Brighi N, et al. Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors. Current Oncology 30: 1381-1394, No. 2, 18 Jan 2023. Available from: URL: https://​www.​mdpi.​com/​journal/​curroncol
Metadaten
Titel
Capecitabine/temozolomide
Nausea, diarrhoea and thrombocytopenia : 2 case reports
Publikationsdatum
01.11.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-49472-6

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

BBV-152

Case report

Lamotrigine

Case report

Multiple drugs

Case report

Antibacterials